Thanks bfw! I'll just re-post my thoughts to your message.

The forest plot looks amazing. Benefit clearly trending in the right direction for everything except there was no effect on stroke. 

As expected, apabetalone increased HDL-C and decreased alkaline phosphatase. 

No statin synergy on 3-point MACE.

Biggest thing that caught my eye was 50% RRR for 3-point MACE in those patients w/ baseline eGFR<60. 

No significant effects on glucose, HbA1c or LDL-C, though these increased more in the placebo than apabetalone groups. No difference in hsCRP.